VIDEO: Sacituzumab govitecan effective regardless of Trop-2 expression level
Click Here to Manage Email Alerts
Results presented from TROPiCS-02 showed that sacituzumab govitecan was effective in a subset of patients with breast cancer regardless of Trop-2 expression level, according to data presented at San Antonio Breast Cancer Symposium.
“TROPiCS-02 was a phase 3 trial that had compared sacituzumab govitecan [Trodelvy, Gilead], the Trop-2-directed [antibody-drug conjugate], to standard chemotherapy in patients with pretreated metastatic hormone receptor-positive breast cancer,” Sara M. Tolaney, MD, MPH, chief of the division of breast oncology at Susan F. Smith Center for Women's Cancers in the Dana Farber Cancer Institute, told Healio.
Data from the study was previously presented at European Society for Medical Oncology and ASCO in 2022, according to Tolaney.
“Data was presented showing levels of Trop-2 expression and associated benefits, and we did actually see that sacituzumab outperformed standard care chemotherapy irrespective of Trop-2 level, so whether you were high Trop-2 or low Trop-2, sacituzumab still did better than chemotherapy,” Tolaney said, adding that this data was consistent with previously presented studies.
“I think at this point in time, it really suggests that we do not need to be testing for Trop-2 expression for predicting with patients should benefit from sacituzumab, since it does seem like all comers did benefit,” she said.
Collapse
Rugo HS, et al. Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (pts) with HR+/HER2– metastatic breast cancer. Presented at: San Antonio Breast Cancer Symposium; Dec. 6-10, 2022.
Read more about
Click Here to Manage Email Alerts